Patents by Inventor Alessia Santoprete
Alessia Santoprete has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230303625Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: September 27, 2022Publication date: September 28, 2023Applicant: Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole HA, Hyewon Youm, Mark W. EMBREY, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. GILBERT, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11725036Abstract: A biologically active single chain Relaxin peptide having the formula Nter-Ac-L-E-G-R-E-K-V-R-A-X19-I-X21-X22-E-G-X25-S-T-F-S-X30-R-A-X33-NH2-Cter, or a salt of solvate thereof, is described.Type: GrantFiled: October 30, 2020Date of Patent: August 15, 2023Assignee: SanofiInventors: Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
-
Patent number: 11530244Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: June 20, 2019Date of Patent: December 20, 2022Assignees: Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11306125Abstract: Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g.Type: GrantFiled: June 20, 2019Date of Patent: April 19, 2022Assignee: Merck Sharp & Dohme Corp.Inventors: Yusheng Xiong, Thomas Joseph Tucker, Chengwei Wu, Elisabetta Bianchi, Danila Branca, Angela Dawn Kerekes, Abbas M. Walji, Hubert B. Josien, Fa-Xiang Ding, Hyewon Youm, Alessia Santoprete, Raffaele Ingenito
-
Publication number: 20210292387Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-AC-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S- X27-X28-X29-X30-X31-X32-X33-NH2-Cter or a salt or solvate thereof. It also concerns a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.Type: ApplicationFiled: October 30, 2020Publication date: September 23, 2021Inventors: Olivier DUCLOS, Stéphane ILLIANO, Sergio MALLART, Claire MINOLETTI-HOCHEPIED, Elisabetta BIANCHI, Raffaele INGENITO, Paola MAGOTTI, Alessia SANTOPRETE
-
Publication number: 20210284694Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: ApplicationFiled: June 20, 2019Publication date: September 16, 2021Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Publication number: 20210214395Abstract: Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g.Type: ApplicationFiled: June 20, 2019Publication date: July 15, 2021Inventors: Yusheng Xiong, Thomas Joseph Tucker, Chengwei Wu, Elisabetta Bianchi, Danila Branca, Angela Dawn Kerekes, Abbas M. Walji, Hubert B. Josien, Fa-Xiang Ding, Hyewon Youm, Alessia Santoprete, Raffaele Ingenito
-
Patent number: 10988524Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.Type: GrantFiled: January 31, 2019Date of Patent: April 27, 2021Assignee: SANOFIInventors: Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Olivier Duclos, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
-
Patent number: 10988523Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.Type: GrantFiled: January 31, 2019Date of Patent: April 27, 2021Assignee: SANOFIInventors: Denis Brasseur, Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
-
Patent number: 10961295Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one biologically active single chain Relaxin peptide. Uses of the peptide or the pharmaceutical composition as a medicament are also provided.Type: GrantFiled: January 31, 2019Date of Patent: March 30, 2021Assignee: SANOFIInventors: Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
-
Publication number: 20190233494Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30—X31—X32—X33—NH2—Cter or a salt or solvate thereof. It also concerns a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.Type: ApplicationFiled: January 31, 2019Publication date: August 1, 2019Inventors: Olivier DUCLOS, Stéphane ILLIANO, Sergio MALLART, Claire MINOLETTI-HOCHEPIED, Elisabetta BIANCHI, Raffaele INGENITO, Paola MAGOTTI, Alessia SANTOPRETE
-
Publication number: 20190233493Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I): Nter-Ac-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(K)d-(X35)e-(gE)f-X37-Cter; or a salt or solvate thereof. It also concerns a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.Type: ApplicationFiled: January 31, 2019Publication date: August 1, 2019Inventors: Denis Brasseur, Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Frank Marguet, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
-
Publication number: 20190233495Abstract: The present invention relates to a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO:65): Nter-X-(E)a-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-R-(X32)b-(X33)c-(X34)d-NH2-Cter It also concerns a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof, and the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition, for its use as a medicament.Type: ApplicationFiled: January 31, 2019Publication date: August 1, 2019Inventors: Stéphane ILLIANO, Sergio MALLART, Claire MINOLETTI-HOCHEPIED, Frank MARGUET, Olivier DUCLOS, Elisabetta BIANCHI, Raffaele INGENITO, Paola MAGOTTI, Alessia SANTOPRETE
-
Patent number: 9593155Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.Type: GrantFiled: April 14, 2015Date of Patent: March 14, 2017Assignees: MERCK SHARP & DOHME CORP., MSD ITALIA S.R.L., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Paul E. Carrington, George J. Eiermann, Donald J. Marsh, Joseph M. Metzger, Alessandro Pocai, Ranabir Sinha Roy, Elisabetta Bianchi, Paolo Ingallinella, Antonello Pessi, Alessia Santoprete, Elena Capito, Richard Dimarchi, Brian Ward
-
Publication number: 20120165503Abstract: Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.Type: ApplicationFiled: December 18, 2009Publication date: June 28, 2012Inventors: Paul E. Carrington, George Eiermann, Donald Marsh, Joseph Metzger, Alessandro Pocai, Ranabir Sinha Roy, Bianchi Bianchi, Paolo Ingallinella, Antonello Pessi, Alessia Santoprete, Elena Capito, Richard Dimarchi, Brian Ward